Narula Sanjeev
Known title: Chief Financial & Bus. OfficerCIK: 0001820590
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Viatris Wins FDA Approval for RYZUMVI and Advances Pacira Deal. Viatris secured U.S. FDA approval for RYZUMVI, a treatment for presbyopia, which is relevant to its partnership with Opus Genetics. The company is also moving forward with a deal involving Pacira, a development analysts are watching closely. These moves add to the company's pipeline and strategic direction.
Transaction History
| PHAT | ▼ Sell | Tax Withholding | 13,485 | $91K | 10/6/2026 | View on chart |
| PHAT | ▲ Buy | Grant | 82,715 | $0 | 1/2/2026 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 38,889 | $0 | 3/4/2023 | View on chart |
| VTRS | ▼ Sell | Tax Withholding | 16,909 | $188K | 3/4/2023 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 1,398 | $0 | 3/4/2023 | View on chart |
| VTRS | ▼ Sell | Tax Withholding | 608 | $7K | 3/4/2023 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 26,125 | $0 | 3/2/2023 | View on chart |
| VTRS | ▼ Sell | Tax Withholding | 11,360 | $126K | 3/2/2023 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 2,067 | $0 | 3/2/2023 | View on chart |
| VTRS | ▼ Sell | Tax Withholding | 899 | $10K | 3/2/2023 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 21,246 | $0 | 2/27/2023 | View on chart |
| VTRS | ▼ Sell | Tax Withholding | 674 | $8K | 2/27/2023 | View on chart |
| VTRS | ▼ Sell | Tax Withholding | 9,326 | $104K | 2/27/2023 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 1,550 | $0 | 2/27/2023 | View on chart |
| VTRS | ▼ Sell | Tax Withholding | 272 | $3K | 3/2/2022 | View on chart |
| VTRS | ▼ Sell | Tax Withholding | 11,415 | $120K | 3/2/2022 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 625 | $0 | 3/2/2022 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 26,126 | $0 | 3/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
PHAT launches Phase 3 study for VOQUEZNA in GERD
Phathom Pharmaceuticals has begun a Phase 3 trial of VOQUEZNA, a drug aimed at treating non‑erosive gastro‑esophageal reflux disease on an as‑needed basis. The study is a critical step toward regulatory approval and could expand the company’s product portfolio. The move follows earlier development phases and may influence investor perception of the company’s growth prospects.
PHAT launches Phase 3 study for VOQUEZNA in GERD. Phathom Pharmaceuticals has begun a Phase 3 trial of VOQUEZNA, a drug aimed at treating non‑erosive gastro‑esophageal reflux disease on an as‑needed basis. The study is a critical step toward regulatory approval and could expand the company’s product portfolio. The move follows earlier development phases and may influence investor perception of the company’s growth prospects.